Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „Substrates“
Suchtreffer
Begriffe & Kennungen
Cotellic · 4.5 · CYP1A2 substrates
Eintrag öffnenCotellic · 4.5 · CYP3A and CYP2D6 substrates
Eintrag öffnenCotellic · 4.5 · In vitro, cobimetinib is a potential inducer of CYP1A2 and may therefore reduce the exposure of substrates of
Eintrag öffnenCresemba · 4.5 · Isavuconazole is an inhibitor in vitro of BCRP, and plasma concentrations of substrates of BCRP may therefore
Eintrag öffnenCresemba · 4.5 · Isavuconazole is an inhibitor in vitro of BCRP, and plasma concentrations of substrates of BCRP may therefore
Eintrag öffnenCresemba · 4.5 · Uridine diphosphate-glucuronosyltransferases (UGT) substrates
Eintrag öffnenCresemba · 4.5 · Uridine diphosphate-glucuronosyltransferases (UGT) substrates
Eintrag öffnenDarunavir Krka · 4.5 · Ritonavir inhibits the transporters P-glycoprotein, OATP1B1 and OATP1B3, and co-administration with substrates
Eintrag öffnenDarunavir Krka · 4.5 · Ritonavir inhibits the transporters P-glycoprotein, OATP1B1 and OATP1B3, and co-administration with substrates
Eintrag öffnenDarunavir Viatris (previously Darunavir Mylan) · 4.5 · Ritonavir inhibits the transporters P-glycoprotein, OATP1B1 and OATP1B3, and co-administration with substrates
Eintrag öffnenDarunavir Viatris (previously Darunavir Mylan) · 4.5 · Ritonavir inhibits the transporters P-glycoprotein, OATP1B1 and OATP1B3, and co-administration with substrates
Eintrag öffnenDiacomit · 4.5 · Co-administration with CYP3A4 substrates with a narrow therapeutic index should be avoided due to the markedly
Eintrag öffnenDiacomit · 4.5 · Co-administration with CYP3A4 substrates with a narrow therapeutic index should be avoided due to the markedly
Eintrag öffnenDiacomit · 4.5 · Co-administration with CYP3A4 substrates with a narrow therapeutic index should be avoided due to the markedly
Eintrag öffnenDiacomit · 4.5 · Co-administration with CYP3A4 substrates with a narrow therapeutic index should be avoided due to the markedly
Eintrag öffnenDificlir · 4.5 · Effect of fidaxomicin on P-gp substrates
Eintrag öffnenDificlir · 4.5 · Effect of fidaxomicin on P-gp substrates
Eintrag öffnenDovato · 4.3 · Co-administration with medicinal products with narrow therapeutic windows, that are substrates of organic cati
Eintrag öffnenDovprela (previously Pretomanid FGK) · 4.5 · Effect on CYP2C8, 2C9 and 2C19 substrates In vitro studies show that pretomanid is an inducer of CYP2C8 while
Eintrag öffnenDovprela (previously Pretomanid FGK) · 4.5 · Effect on OAT3, OATP1B3, P-gp and BCRP substrates Pretomanid is an inhibitor of the OAT3 transporter in vitro,
Eintrag öffnen